Novo Nordisk presents full results from FLOW trial of Ozempic

Novo Nordisk presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease, or CKD, at the 84th Annual Scientific Sessions of the American Diabetes Association, or ADA. The double-blind, randomized, placebo-controlled trial, which enrolled 3,533 people with type 2 diabetes and CKD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. The primary outcome was major kidney disease events, a composite of onset of kidney failure, a sustained 50% or greater reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. “Treating serious comorbidities like chronic kidney disease is critical to improving treatment outcomes for people with type 2 diabetes. The results from the FLOW trial represent important data, as we look to better understand what GLP-1 treatment options could mean for this patient population. Leveraging our deep expertise in cardiometabolic science, we are proud to continue building strong clinical evidence on the strength and versatility of semaglutide to deliver results for people living with serious chronic diseases,” said Anna Windle, PhD, senior vice president clinical development, Medical & Regulatory Affairs at Novo Nordisk.